Trial Profile

A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions

Most Recent Events

27 Oct 2025 Actual primary completion date changed from 22 Jan 2020 to 27 Dec 2019.
27 Oct 2025 Status changed from active, no longer recruiting to completed.
29 Jun 2023 Planned End Date changed from 1 Mar 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com